Publications

Detailed Information

Changes of psychiatric parameters and their relationships by oral isotretinoin in acne patients

DC Field Value Language
dc.contributor.authorHahm, Bong Jin-
dc.contributor.authorMin, Seong Uk-
dc.contributor.authorYoon, Mi Young-
dc.contributor.authorShin, Yong Wook-
dc.contributor.authorJung, Jae Yoon-
dc.contributor.authorSuh, Dae Hun-
dc.contributor.authorKim, Jin Sook-
dc.date.accessioned2012-07-03T04:26:03Z-
dc.date.available2012-07-03T04:26:03Z-
dc.date.issued2009-05-
dc.identifier.citationJOURNAL OF DERMATOLOGY; Vol.36(5); 255-261ko_KR
dc.identifier.issn0385-2407-
dc.identifier.urihttps://hdl.handle.net/10371/78210-
dc.description.abstractOral isotretinoin is a highly effective agent for the treatment of moderate to severe acne, but ever since oral isotretinoin was introduced as a modality for acne, the relationship between oral isotretinoin therapy and psychiatric problems, especially depression, has been controversial. The purposes of this study were to know the acute effects of oral isotretinoin therapy on psychiatric symptoms and to investigate the relationships among them, which have not been reported in the published work. This cohort study included 38 acne patients who started oral isotretinoin therapy. Individual patients were examined before administering oral isotretinoin and 2 and 8 weeks after commencement. Acne severity was graded using the Leeds revised acne grading system. Acute psychiatric effects of oral isotretinoin were assessed using a questionnaire authorized by two psychiatrists. This questionnaire included assessments of acne-related quality of life (Assessment of the Psychological and Social Effects of Acne [APSEA]), depression (Beck`s depression inventory [BDI]), anxiety (Beck`s anxiety inventory [BAI]) and psychopathology (Symptomchecklist-90-revised [SCL-90-R]). Acne grading and APSEA showed similar change patterns. Both improved after 8 weeks of oral isotretinoin treatment. On the other hand, the severity of depression decreased after 2 weeks of treatment. A significant correlation was found between BDI and APSEA, but no correlation was found between BDI and acne grade. These results indicate that oral isotretinoin therapy alleviates depressive symptoms. Improvements in depression are directly related to acne-related life quality improvements rather than to improvement in acne grade.ko_KR
dc.language.isoenko_KR
dc.publisherWILEY-BLACKWELL PUBLISHING, INCko_KR
dc.subjectacneko_KR
dc.subjectdepressionko_KR
dc.subjectisotretinoinko_KR
dc.subjectpsychiatryko_KR
dc.titleChanges of psychiatric parameters and their relationships by oral isotretinoin in acne patientsko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor함봉진-
dc.contributor.AlternativeAuthor민성욱-
dc.contributor.AlternativeAuthor윤미영-
dc.contributor.AlternativeAuthor신용욱-
dc.contributor.AlternativeAuthor김진숙-
dc.contributor.AlternativeAuthor정재윤-
dc.contributor.AlternativeAuthor서대헌-
dc.identifier.doi10.1111/j.1346-8138.2009.00635.x-
dc.citation.journaltitleJOURNAL OF DERMATOLOGY-
dc.description.citedreferenceANTONIO J, 2007, J EUR ACAD DERMATOL, V21, P556-
dc.description.citedreferenceKaymak Y, 2006, J EUR ACAD DERMATOL, V20, P1256, DOI 10.1111/j.1468-3083.2006.01784.x-
dc.description.citedreferenceO`Reilly KC, 2006, NEUROPSYCHOPHARMACOL, V31, P1919, DOI 10.1038/sj.npp.1300998-
dc.description.citedreferenceYen JY, 2006, PSYCHIAT CLIN NEUROS, V60, P147-
dc.description.citedreferenceFerguson SA, 2005, TOXICOL SCI, V87, P451, DOI 10.1093/toxsci/kfi262-
dc.description.citedreferenceChia CY, 2005, ARCH DERMATOL, V141, P557-
dc.description.citedreferenceAarstad HJ, 2005, ACTA OTO-LARYNGOL, V125, P557, DOI 10.1080/00016480510027547-
dc.description.citedreferenceSahin M, 2005, NEUROTOX RES, V7, P243-
dc.description.citedreferenceCrandall J, 2004, P NATL ACAD SCI USA, V101, P5111, DOI 10.1073/pnas.0306336101-
dc.description.citedreferenceSakai Y, 2004, ANN NY ACAD SCI, V1021, P436, DOI 10.1196/annals.1308.059-
dc.description.citedreferenceWysowski DK, 2001, J AM ACAD DERMATOL, V45, P515-
dc.description.citedreferenceWysowski DK, 2001, NEW ENGL J MED, V344, P460-
dc.description.citedreferenceJick SS, 2000, ARCH DERMATOL, V136, P1231-
dc.description.citedreferencePatton GC, 2000, AUST NZ J PSYCHIAT, V34, P741-
dc.description.citedreferenceLayton AM, 2000, J DERMATOL TREAT, V11, P3-
dc.description.citedreferenceKellett SC, 1999, BRIT J DERMATOL, V140, P273-
dc.description.citedreferenceMIDDELKOOP T, 1999, J PHARM PRACT, V12, P374-
dc.description.citedreferenceO`Brien SC, 1998, J DERMATOL TREAT, V9, P215-
dc.description.citedreferenceGupta MA, 1998, BRIT J DERMATOL, V139, P846-
dc.description.citedreferenceZouboulis CC, 1998, DERMATOLOGY, V196, P21-
dc.description.citedreferenceLayton AM, 1997, DERMATOLOGY, V195, P15-
dc.description.citedreferenceBYRNE A, 1995, CAN J PSYCHIAT, V40, P567-
dc.description.citedreferenceSITZMANN JH, 1995, BRIT J DERMATOL, V133, P241-
dc.description.citedreferenceKOO J, 1995, J AM ACAD DERMATOL, V32, pS26-
dc.description.citedreferenceRHEE MK, 1995, KOR J PSYCHOPATHOL, V4, P77-
dc.description.citedreferenceALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30-
dc.description.citedreferenceHULL SM, 1991, CLIN EXP DERMATOL, V16, P210-
dc.description.citedreferenceCRETTAZ M, 1990, BIOCHEM J, V272, P391-
dc.description.citedreferenceBECK S, 1990, MANUAL BECK ANXIETY-
dc.description.citedreferenceHIRSCHELSCHOLZ S, 1989, BRIT J DERMATOL, V120, P639-
dc.description.citedreferenceRUBINOW DR, 1987, J AM ACAD DERMATOL, V17, P25-
dc.description.citedreferenceDEROGATIS S, 1983, SCL90R CLIN PYCH RES-
dc.description.citedreferenceHAHN H, 1982, J KOREAN NEUROPSYCHI, V25, P487-
dc.description.citedreferenceBECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561-
dc.description.tc9-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share